- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Ingrid Hall discusses the CDC's involvement in active surveillance for localized prostate cancer. She highlights the 2011 State-of-the-Science Conference and subsequent research initiatives aimed at addressing gaps identified by the consensus panel, and emphasizes the CDC's commitment to supporti...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Timothy Wilt discusses the potential impact of changing prostate cancer nomenclature on screening guidelines. Dr. Wilt notes that current screening rates remain high despite limited net benefit. He suggests that changes in clinical practice guidelines may be driven more by advocacy than science....
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Hashim Ahmed discusses the UK's approach to prostate cancer diagnosis using MRI-based screening. Dr. Ahmed presents data showing that combining MRI with PSA density can significantly reduce unnecessary biopsies, particularly for PIRADS 1, 2, and low PSA density PIRADS 3 cases. He proposes an inte...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts explore various aspects of prostate cancer screening, diagnosis, and management. They compare approaches in the UK and US, noting differences in screening practices and attitudes towards low-grade cancers. The discussion concludes with a debate about the histopathological criteria for dia...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts debate the effectiveness of biomarkers in distinguishing between different grades of prostate cancer, particularly in active surveillance cohorts. The conversation highlights the difficulty in identifying the small percentage of high-risk patients within low-risk cohorts. The discussion c...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Felix Feng discusses the limitations of genomics and AI in resolving the prostate cancer nomenclature question. He emphasizes that current genomic tools have not proven effective in active surveillance contexts, citing studies showing limited prognostic value beyond clinical variables. Dr. Feng e...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts explore the complexities of prostate cancer diagnosis and classification. The participants debate the use of terms like "cancer" and "carcinoma," and discuss the potential for reclassifying some Grade Group 1 cancers. They explore the historical and biological basis for using basal cell l...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts explore the potential clinical implications of reclassifying low-grade prostate cancer. The group anticipates decreased treatment rates for Grade Group 1 disease, reduced patient burden, and less intensive surveillance. They also consider risks such as increased loss to follow-up. The con...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts discuss the potential impacts of changing the nomenclature for low-grade prostate cancer. The group concludes that advocacy organizations are unlikely to be threatened by the change, as it may improve quality of life without affecting survival. They raise concerns about certain population...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts discuss the potential non-clinical implications of changing prostate cancer nomenclature. The group identifies positive outcomes such as reduced patient anxiety and costs, and potentially improved insurance access. Negative consequences could include decreased philanthropy and grant fundi...
|
